



**Figure S3.** BCI and JNKi effects in MPNST cells. **A**, Immunoblot of total levels ERK, JNK, and p38 in iHSC and in MPNST cell line ST8814 and S462.TY after BCI treatment. **B**, Immunoblot analysis of MAPK signaling and proliferation marker (cyclin D1) after STS26T MPNST cells were starved overnight, pre-incubated with BCI (2 uM) for 60 mins then stimulated with DMEM and 10% FBS for 15 mins. **C**, Human MPNST cell line ST8814 treated with JNK inhibitor JNK-IN-8. Cell line ST8814 was serum starved overnight and treated with JNK-IN-8 in DMEM and 10% FBS then viability was measured with the MTS assay (OD at 490 nm) 3 days after treatment. **D**, Immunoblot analysis of p-c-jun after JNK inhibition. **E**, Cell line ST8814 treated with JNK inhibitor SP600125 in combination with BCI. **F**, Immunoblot analysis of p-c-jun after JNK inhibition with SP600125. (\*) represents  $P < 0.05$ ,  $n = 6$ .